Helomics | GenomeWeb

Helomics

The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms. 

The company also intends to eventually offer the two additions, which expand the granularity of its live-cell analysis platform, for clinical use.

Helomics will provide its technology to the GENE Consortium, formed to support the UK's 100,000 Genomes Project.

Helomics' tumor profiling products and services, including ChemoFx, will be available to more than 700,000 Prime Health Services providers.

Formerly called Precision Therapeutics, the company recently received a $60 million investment and ushered in new management.

NEW YORK (GenomeWeb) – Precision Therapeutics today announced a $60 million investment and a new name, Helomics.

NEW YORK (GenomeWeb) – Med BioGene today announced that it is ready to initiate proceedings against its commercial partner Precision Therapeutics to enforce a C$1 million (US$920,000) milestone payment due to Med BioGene.

NEW YORK (GenomeWeb News) – Med BioGene today said that its commercial partner, Precision Therapeutics, has been certified to perform Med BioGene's lung cancer test out of Precision's Pittsburgh laboratory.

Almac Diagnostics said this week that a group led by partner Precision Therapeutics has independently validated Almac's ColDx test for stage II colorectal cancer recurrence ahead of its full commercialization in the US.

NEW YORK (GenomeWeb News) – Med BioGene today said that it and its commercial partner, Precision Therapeutics, have settled litigation with Signal Genetics and its Respira Health subsidiary, ending a dispute over an alleged breach of contract that began more than two years ago.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.